Список проголосовавших за комментарий " Threshold Pharma will merge with Molecular Templates in an all-stock transaction; Longitude Capital will invest $20 mln at the close of the transaction, including the receipt of additional equity financing commitments of $20 mln (0.61)<p>The transaction will result in a combined company focused on the development of novel treatments for cancer.</p><ul><li>Longitude Capital, a U.S. based venture capital firm, <strong>will invest $20 mln at the close of the transaction</strong>, subject to certain conditions, including the receipt of additional equity financing commitments of $20 mln.</li><li>On a pro forma basis and based upon the number of shares of common stock to be issued in the merger, current Threshold shareholders would own ~34.4% of the combined company and current Molecular Templates shareholders would own ~65.6% of the combined company although the actual allocation will be subject to adjustment based on Threshold's net cash balance.</li><li>Concurrent with the execution of the Merger Agreement, Threshold made a bridge loan to Molecular Templates in the principal amount of $2 mln.<ul><li>In the event that the transaction does not close by May 31, 2017, <strong>Threshold has agreed to make available further funding of up to $2 mln </strong>on the same terms upon mutual agreement.</li></ul></li><li>The merger is expected to close in 2Q17.</li></ul><p><em>Co will host a webcast to discuss on March 17, 2017, at 8:30 a.m. ET</em></p>"